Home

Argumentative issues of chronic obstructive pulmonary disease (materials of panel of experts, Far Eastern Federal District from 06/13/2018, Vladivostok)

Written by Nevzorova V.A., Avdeev S.N., Kondrashova N.M., Shumatov V.B., Kudelya L.M., Sukhanova G.I., Kinyaykin M.F., Naumova I.V., Kudryavtseva V.A., Khizhnyak Yu.Yu., Musatov I.B.

  UDK: 616.24–007.271–036.12 | DOI: 10.17238/PmJ1609-1175.2019.1.5–12  Pages: 5–12 | Full text PDF | Open PDF 

Annotation:

The article represents argumentative issues of Chronic Obstructive Pulmonary Disease (COPD) treatment which is a global problem of modern medicine. According to WHO data COPD is the third leading cause of death worldwide, annually about 2.8 million people die because of this disease, and over 20 years this statistics never changed. In developed countries the highest costs for health systems in the treatment of respiratory diseases are associated with COPD which affect the course of this disease causing an irreversible progressive decline in lung function, deteriorating quality of life, increasing the frequency of readmissions and mortality. Thus, the prevention of exacerbations of COPD is of social and economic importance and should be a priority in the treatment of this disease.

Links to authors:

V.A. Nevzorova1, S.N. Avdeev2, N.M. Kondrashova1, V.B. Shumatov1, L.M. Kudelya3, G.I. Sukhanova1, M.F. Kinyaykin1, I.V. Naumova1, V.A. Kudryavtseva4, Yu.Yu. Khizhnyak5, I.B. Musatov6
1 Pacific State Medical University (2 Ostryakova Ave. Vladivostok 690002 Russian Federation),
2 I.M. Sechenov First Moscow State Medical University (8/2 Trubetskaya St. Moscow 119991 Russian Federation),
3 State Novosibirsk Regional Clinical Hospital (130 Nemirovicha-Danchenko St. Novosibirsk 630087 Russian Federation),
4 Vladivostok Clinical and Diagnostic Center (131 Svetlanskaya St. Vladivostok 690001 Russian Federation),
5 Yuzhno-Sakhalinsk City Outpatient Clinic No. 4 (200 Komsomolskaya St. Yuzhno-Sakhalinsk 693020 Russian Federation), 6 Spassk City Outpatient Clinic (29 Leninskaya St. Spassk-Dalniy 692245 Russian Federation)


1. WHO. Cancer. 2018. URL: http://www.who.int/mediacentre/ factsheets/fs297/en/ (date of access: 03.11.2018).
2. WHO. The top 10 causes of deth. 2018. URL: http://www.who. int/mediacentre/factsheets/fs310/en/ (date of access: 03.11.2018).
3. Krysanov I.S. Analysis the cost of chronic obstructive pulmonary disease in Russian Federation // Kachestvennaya Klinicheskaya praktika. 2014. No. 2. P. 51–56.
4. Rosstat. Demographic yearbook. URL: http://www.gks.ru/ free_doc/new_site/population/demo/smert.htm (date of access:
03.12.2018).
5. Chronic obstructive pulmonary disease: Federal clinical guidelines. 2018. URL: http://spulmo.ru/obrazovatelnye-resursy/federalnye- klinicheskie-rekomendatsii/ (date of access: 03.12.2018).
6. Andersson F., Borg S., Jansson S.A. [et al.]. The costs of exacerbations in chronic obstructive pulmonary disease // Respiratory Medicine. 2002. Vol. 96. P. 700–708.
7. Braido F., Scichilone N., Lavorini F. [et al.]. Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association – GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN) // Asthma Research and Practice. 2016. No. 2. P. 12.
8. Brusselle G., Price D., Gruffydd-Jones K. [et al.]. The inevitable drift to triple therapy in COPD: An analysis of prescribing pathways in the UK // International Journal of COPD. 2015. Vol. 10. P. 2207–2217.
9. Dransfield M.T. Bourbeau J., Jones P.W. [et al.]. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: Two replicate doubleblind, parallel-group, randomised controlled trials // Lancet Respir. Med. 2013. Vol. 1, No. 3. P. 210–223.
10. EMA: PRAC reviews known risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease. URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ news_and_events/news/2016/03/news_detail_002491. jsp&mid=WC0b01ac058004d5c1 (date of access: 11.11.2018).
11. Ferguson G.T., Rabe K.F., Martinez F.J. [et al.]. Triple combination of budesonide/glycopyrrolate /formoterol fumarate using co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): A doubleblind, parallel-group, randomised controlled trial // Lancet Respir. Med. 2018. URL: https://www.thelancet.com/journals/ lanres/article/PIIS2213-2600(18)30327-8/fulltext (date of access:
03.11.2018).
12. Festic E., Bansal V., Gupta E. [et al.]. Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients: Systematic review and meta-analysis // COPD. 2016. Vol. 13, No. 3. P. 312–326.
13. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. URL: https://goldcopd.org/wp-content/ uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS. pdf (date of access: 03.11.2018).
14. GOLD 2017. URL: https://goldcopd.org/wp-content/uploads/ 2016/12/wms-GOLD-2017-Pocket-Guide.pdf (date of access: 11.11.2018).
15. Hastie A.T., Martinez F.J., Curtis J.L. [et al.]. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: An analysis of the SPIROMICS cohort // Lancet Respir. Med. 2017. Vol. 5, No. 12. P. 956–967.
16. Kew K.M., Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease // Cochrane Database of Systematic Reviews. 2014. 3. CD010115. URL: https://doi.org/10.1002/14651858.CD010115.pub2 (date of access:
11.11.2018).
17. King P.T. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer // Clin. Transl. Med. 2015. Vol. 4, No. 1. P. 68. doi: 10.1186/s40169-015- 0068-z.
18. Lipson D.A, Barnhart F., Brealey N. [et al.]. Once-daily singleinhaler triple versus dual therapy in patients with COPD // N. Engl. J. Med. 2018. Vol. 378, No. 18. Р. 1671–1680.
19. Lipworth B., Kuo C.R., Jabbal S. Current appraisal of single inhaler triple therapy in COPD // Int. J. Chron. Obstruct. Pulmon. Dis. 2018. Vol. 13. P. 3003–3009.
20. Papi A., Vestbo J., Fabbri L. [et al.]. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial // Lancet. 2018. Vol. 391, No. 10125. P. 1076–1084.
21. Polosukhin V.V., Richmond B.W., Du R.H. [et al.]. Secretory IgA deficiency in individual small airways is associated with persistent inflammation and remodeling // Am. J. Respir. Crit. Care Med. 2017. Vol. 195, No. 8. P. 1010–1021.
22. Price D., West D., Brusselle G. [et al.]. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns // International Journal of COPD. 2014. No. 9. P. 889–905.
23. Siddiqui S.H., Pavord I.D., Barnes N.C. [et al.]. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids // Int. J. Chron. Obstruct. Pulmon. Dis. 2018. Vol. 13. P. 3669–3676.
24. Singh D., Nicolini G., Bindi E. [et al.]. Comparison of extra fine beclomethasone dipropionate/formoterol fumarate versus other double combinations on reduction of moderate/severe exacerbations // BMC Pulm. Med. 2014. doi: 10.1186/1471-2466-14-43 (date of access: 11.11.2018).
25. Singh D., Papi A., Corradi M. [et al.]. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double- blind, parallel group, randomised controlled trial // Lancet. 2016. Vol. 388. P. 963–973.
26. Sonnappa S., Martin R., Israel E. [et al.]. Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids // PLoS One. 2017. URL: https://doi.org/10.1371/journal.pone.0178112 (date of access:
11.11.2018).
27. Stănescu D., Sanna A., Veriter C. [et al.]. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils // Thorax. 1996. Vol. 51, No. 3. P. 267–271.
28. Vedel-Krogh S., Nielsen S.F., Lange P. [et al.]. Blood eosinophils and COPD exacerbations // Am. J. Respir. Crit. Care Med. 2016. Vol. 193, No. 9. P. 965–974.
29. Vestbo J., Papi A., Corradi M. [et al.]. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A doubleblind, parallel group, randomised controlled trial // Lancet. 2017. Vol. 389. P. 1919–1929.
30. WHO. URL: http://www.who.int/en/news-room/fact-sheets/ detail/chronic-obstructive-pulmonary-disease-(copd), https:// www.lung.org/assets/documents/research/copd-trend-report. pdf (date of access: 03.11.2018).

PUBLISHER: "MEDITSYNA DV"

Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.